Opendata, web and dolomites

MAINTRAC-Auto

MAINTRAC-Auto: Automatization and validation of a liquid biopsy assay “Maintrac-AUTO CTC-analyser” for predictive real time monitoring and success control of solid tumor cancer therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MAINTRAC-Auto project word cloud

Explore the words cloud of the MAINTRAC-Auto project. It provides you a very rough idea of what is the project "MAINTRAC-Auto" about.

sales    arise    assays    prognosis    analyser    manual    individualize    model    relevance    obvious    ineffective    cells    maintenance    upscaling    oncology    forecasts    efficiency    offers    automatic    commercially    relapse    12bn    savings    reducing    clinical    equivalence    circulating    causes    revenue    primary    ctc    families    ctcs    automated    standardized    economic    course    suffering    treatment    specialists    diagnose    innovation    patient    auto    clinically    therapies    diseases    estimate    biomarker    assay    drastically    indicator    direct    demand    effectiveness    regulatory    worldwide    death    approved    tumor    track    business    individual    acceptance    readiness    diagnostics    2020    meet    care    implications    validation    precision    adequately    penetration    public    health    appropriate    series    patients    innovative    cancer    therapy    us    progression    monitoring    launch    big    maintrac    initial    disease    reimbursement    meanwhile    substantially    symptoms    market    breast   

Project "MAINTRAC-Auto" data sheet

The following table provides information about the project.

Coordinator
SIMFO SPEZIELLE IMMUNOLOGIE FORSCHUNG UND ENTWICKLUNG GMBH 

Organization address
address: KURPROMENADE 2
city: BAYREUTH
postcode: 95448
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.simfo.de
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2016-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SIMFO SPEZIELLE IMMUNOLOGIE FORSCHUNG UND ENTWICKLUNG GMBH DE (BAYREUTH) coordinator 50˙000.00

Map

 Project objective

Worldwide cancer is one of the leading causes of death and the need for more effective therapies is crucial. New precision diagnostics can identify and characterize the disease to individualize the therapy throughout the course of cancer, like our clinically approved Maintrac-CTC assay. Maintrac-CTC can track circulating tumor cells (CTCs) even in primary cancer patients to estimate prognosis and diagnose relapse well before clinical symptoms arise. Meanwhile a fully automated Maintrac AUTO analyser was established and offers a standardized state-of-art biomarker system for direct and better monitoring of disease progression and effectiveness i.e. of the maintenance therapy in breast cancer. We aim to drastically increase both effectiveness (selection of treatment most adequately for individual cancer type and phase) and efficiency (early indicator for the response level to an initial therapy) to avoid ineffective therapies, savings cost for the health care system and substantially reducing patient suffering. The objectives of the innovation project are to achieve series-production readiness and launch the system commercially with the best business model. We aim for acceptance of Maintrac CTC assays by oncology specialists through clinical validation and to achieve reimbursement by public authorities for upscaling and market penetration. In phase 1 we will show equivalence of the automatic system to the established manual method and meet regulatory requirements. In addition business opportunities and appropriate sales model will be evaluated. Forecasts for overall CTC biomarker market estimate a big market with a high demand for innovative products with expected revenue potential of US$ 12bn in 2020. Due to the obvious relevance of cancer diseases for patients, their families as well as economic implications, Maintrac will have an important impact on future cancer disease management.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAINTRAC-AUTO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAINTRAC-AUTO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

PREMSTEM (2020)

Brain injury in the premature born infant: stem cell regeneration research network

Read More